China Shijiazhuang Pharmaceutical Group Co., Ltd. (CSPC) was incorporated by Hebei Pharmaceutical Corporation, Shijiazhuang No. 1 Pharmaceutical Group Co., Ltd. and other two companies on Aug 21, 1997. It’s the first mega pharmaceutical enterprise jointly established by big pharmaceutical enterprises in the medicine industry of China, and it’s also one of the pillar enterprise group of Hebei Province. CSPC Pharma. currently boasts RMB 11.5 billion of assets in total, about 20, 000 employees, and has more than ten affiliates such as Zhongrun Pharma., Weisheng Pharma., Zhongnuo Pharma., Ouyi Pharma., NBP, etc, therein, China Pharmaceutical Group Co., Ltd. – a controlling affiliate established in Hong Kong is the first Chinese pharmaceutical enterprise listed overseas, currently one of the largest pharmaceutical company listed in Hong Kong and one of the Hang Seng Red Chips Index Component stocks, and has been named by world-known Forbes as one of Top 100 Listed Companies with business turnover below USD 1 billion in Asia for two successive times. CSPC Pharma. is a mega pharmaceutical enterprise specialized in science, technology and trading, and mainly engaged in pharmaceutical product development, production and sale. Its key products include antibiotic, vitamin, cardiovascular and cerebrovascular medicine, antipyretic and analgesic drug and respiratory drug, etc, six series in total and nearly 1, 000 varieties, and penicillin series and vitamin series are its dominant products. At present, the annual Vitamin C production capacity has reached 25, 000 tons, 16, 000t for penicillin series of pharmaceutical products, 1, 600 tons for 7-ACA, 6, 000t for amoxicillin, and 8, 000t for caffeine, respectively ranking the first place in the world. CSPC’s sterile injection powder production capacity is 3 billion pieces, 20 billion for tablet, 8 billion for capsule and 1 billion for soft capsule. The output, scale and strength of the dominant products of CSPC Pharma. come out top in China, and CSPC has developed into one of the largest “Chemical Pharmaceutical Manufacturing Bases” and “Comprehensive Preparation Production Bases”. At present, single-variety sales value of 30 products of CSPC Pharma. has exceeded RMB 100 million, and the products are sold around China and more than 60 countries and regions in the world. Since the establishment several decades ago, CSPC has been growing, innovating and progressing, and achieved leaping development and gratifying achievements, and successively won the honorable titles of “Advanced Collective of Chinese Pharmaceutical Industry”, “Advanced Enterprise in Quality and Efficiency”, “Manufacturer with Assured Product Quality”, “National May 1st Labor Award”, “Environment Loving Enterprise of China”, etc. In 2008, CSPC Pharma. realized RMB 10 billion of sales revenue (excluding tax), RMB 1.359 billion of profits payments and tax turnover and RMB 1.117 billion of profits, ranking the 2nd in Chinese pharmaceutical industry; the whole Group earned USD 450 million of foreign exchanges by direct export, ranking the first among Chinese pharmaceutical enterprises. On the regard of R&D, CSPC has successively developed over 90 national-level new drugs relying on its “post-doctoral mobile research center”, “National-level Enterprise Technical Center”, “863 Program” High-tech Industrialization Base and Hebei Provincial Preparation Engineering Technical Center in recent years, involving a great variety of fields such as biotechnology, chiral synthetic drugs, liposome, transdermal preparation, molecular microcapsules, etc. To date, CSPC Pharma. has applied for 200 patents, including more than 10 PCT international patents. Among the rest, the National Class 1 new drug “EBP” with owned intellectual property rights takes the lead in the global market of ischemic cerebral apoplexy therapy, filling a blank of National Class 1 new drug in Hebei Province, and the intellectual property rights thereof are protected in 86 countries around the world. So far, CSPC Pharma. has concluded contracts with two well-known enterprises from the USA and Korea to transfer the rights of using the NBP soft capsules in the markets of Europe, America and Korea. It’s the first case that a Chinese pharmaceutical enterprise transfer pharmaceutical intellectual property rights to the most developed countries in the world, and CSPC won great honor to the nation. In 2008, CSPC., under the leadership and guidance of Ministry of Science and Technology, organized Technical Innovation League for Antibiotic Industry of China, and received the project supports of the national scientific supporting program. Among the significant patent applications for the national “major new drug creation”, 1 innovative new drug hatching base, 3 innovative new drug R&D technology platforms and 6 new drug development projects have settled at CSPC, and CSPC has become the enterprise enjoying the most policy-based project supports in this industry. In terms of quality, CSPC Pharma.has established a self-contained three-level quality control system, and all the drugs have achieved GMP certification, and all the subordinated companies have passed ISO9000, OHSAS18000 and ISO14001 certifications, and the up-to-standard rate of the products has been kept at 100% constantly in the market. Meanwhile, CSPC Pharma. has been engaged in improving the quality connotation by technology, and 6 pharmaceutical products (such as caffeine, vitamin C, VB12, amoxicillin, etc) have achieved COS certification of EU, and obtained a “passport” to the high-end markets in Europe and America. On the aspect of brand building, CSPC boasts two “Well-known Trademarks of China”, i.e. “CSPC” and “Ouyi”; “CSPC” was assessed by World Brand Lab (WBL), one of the world’s five major brand evaluation organizations, and named one of “Top 500 Most Valuable Chinese Brands 2005”; CSPC has been selected “Top 500 Chinese Enterprises” for three successive times and won the title “Chinese Enterprises with the Most Valuable Brand 2008”. Looking ahead, CSPC Pharma. will continue to uphold the enterprise philosophy “All for good medicine, all for mankind’s health”, endeavor in the health of mankind and make contributions to the society with more innovative and better products, and make relentless efforts to build CSPC into a first-rate large-scale modern enterprise in China and one of the World Top 500 Enterprises.